Zenith Abstract at AACR 2017 Meeting April 1-5

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Zenith Abstract at AACR 2017 Meeting April 1-5

posted on Mar 07, 2017 03:41PM

AACR Abstract embargoed at this time until March 31, but here is the title

LB-038 / 1 - Preclinical development and clinical validation of a whole blood pharmacodynamic marker assay for the BET bromodomain inhibitor ZEN-3694 in metastatic castration-resistant prostate cancer (mCRPC) patients

Presenter/Authors:

Laura Tsujikawa, Karen Norek, Cyrus Calosing, Sarah Attwell, Dean Gilham, Nimisha Sharma, Jennifer Tobin, Michelle Haager, Ravi Jahagirdar, Sanjay Lakhotia, Henrik C. Hansen, Eric Campeau. Zenith Epigenetics, Calgary, AB, Canada

Disclosures:

L. Tsujikawa: ; Zenith Epigenetics. ; Resverlogix. K. Norek: ; Zenith Epigenetics. C. Calosing: ; Zenith Epigenetics. S. Attwell: ; Zenith Epigenetics. D. Gilham: ; Resverlogix. N. Sharma: ; Zenith Epigenetics. J. Tobin: ; Zenith Epigenetics. M. Haager: ; Zenith Epigenetics. R. Jahagirdar: ; Zenith Epigenetics. S. Lakhotia: ; Zenith Epigenetics. H.C. Hansen: ; Zenith Epigenetics. E. Campeau: ; Zenith Epigenetics.

4 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply